Antipsychotic Use and Risk of Breast Cancer in Women With Severe Mental Illness: Replication of a Nationwide Nested Case–Control Database Study
Schizophrenia Bulletin · 2024
DOI: 10.1093/schbul/sbae058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Schizophrenia Bulletin, 2024. Verfasst von Marco Solmi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Antipsychotic Agents, Psychotic Disorders, Schizophrenia. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academy of Finland, Swedish Research Council.
Abstract (Originalsprache)
Background and hypothesis Breast cancer is more prevalent in women with severe mental illness than in the general population, and use of prolactin-increasing antipsychotics may be a contributing factor. Study design A nested case–control study was conducted using the Swedish nationwide registers (inpatient/outpatient care, sickness absence, disability pension, prescribed drugs, cancers). All women aged 18–85 years with schizophrenia/schizoaffective/other nonaffective psychotic disorder/bipolar disorder and breast cancer (cases) were matched for age, primary psychiatric diagnosis, and disease duration with five women without cancer (controls). The association between cumulative exposure to prolactin-increasing/prolactin-sparing antipsychotics and breast cancer was analyzed using conditional logistic regression, adjusted for comorbidities and co-medications. Study results Among 132 061 women, 1642 (1.24%) developed breast cancer between 2010 and 2021, at a mean age of 63.3 ± 11.8 years. Compared with 8173 matched controls, the odds of breast cancer increased in women with prior exposure to prolactin-increasing antipsychotics for 1–4 years (adjusted odds ratio [aOR] = 1.20, 95% confidence interval [CI] = 1.03–1.41), and for ≥ 5 years (aOR = 1.47, 95%CI = 1.26–1.71). There were no increased or decreased odds of breast cancer with exposure to prolactin-sparing antipsychotics of either 1–4 years (aOR = 1.17, 95%CI = 0.98–1.40) or ≥5 years (aOR = 0.99, 95%CI = 0.78–1.26). The results were consistent across all sensitivity analyses (ie, according to different age groups, cancer types, and primary psychiatric diagnosis). Conclusions Although causality remains uncertain, exposure to prolactin-elevating antipsychotics for ≥ 1 year was associated with increased odds of breast cancer in women with severe mental illness. When prescribing antipsychotics, a shared decision-making process should consider individual risk factors for breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, University of Ottawa, Ontario, Canada.
- SCIENCES LAB, Department of Mental Health, The Ottawa Hospital, Ontario, Canada.
- Ottawa Hospital Research Institute (OHRI), Clinical Epidemiology Program, University of Ottawa, Ontario, Canada.
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ontario, Canada.
- Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany.
- Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.
ORCID-Profile: Marco Solmi, Markku Lähteenvuo, Antti Tanskanen, Olivier Corbeil, Ellenor Mittendorfer-Rutz, Christoph U Correll, Jari Tiihonen, Heidi Taipale
Förderung
- Academy of Finland
- Swedish Research Council
Zitieren
APA
Solmi, M., Lähteenvuo, M., Tanskanen, A., Corbeil, O., Mittendorfer-Rutz, E., Correll, C. U., Tiihonen, J., & Taipale, H. (2024). Antipsychotic Use and Risk of Breast Cancer in Women With Severe Mental Illness: Replication of a Nationwide Nested Case–Control Database Study. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbae058
Vancouver
Solmi M, Lähteenvuo M, Tanskanen A, Corbeil O, Mittendorfer-Rutz E, Correll CU, et al. Antipsychotic Use and Risk of Breast Cancer in Women With Severe Mental Illness: Replication of a Nationwide Nested Case–Control Database Study. Schizophrenia Bulletin. 2024. doi:10.1093/schbul/sbae058
BibTeX
@article{Solmi2024,
author = {Solmi, Marco and Lähteenvuo, Markku and Tanskanen, Antti and Corbeil, Olivier and Mittendorfer-Rutz, Ellenor and Correll, Christoph U and Tiihonen, Jari and Taipale, Heidi},
title = {Antipsychotic Use and Risk of Breast Cancer in Women With Severe Mental Illness: Replication of a Nationwide Nested Case–Control Database Study},
journal = {Schizophrenia Bulletin},
year = {2024},
doi = {10.1093/schbul/sbae058}
}
EUVIMED